文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

瑞戈非尼联合FOLFIRI方案按UGT1A1基因型调整伊立替康剂量治疗经治转移性结直肠癌的随机对照试验研究方案

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-12-19

本研究为前瞻性、多中心、随机2:1对照临床试验,比较按UGT1A1基因型调整伊立替康剂量的FOLFIRI联合瑞戈非尼120mg与瑞戈非尼120mg单药在经治转移性结直肠癌患者中的疗效与安全性,主要终点为无进展生存期。

要点

  • 瑞戈非尼减量至120mg可减少不良事件。
  • 按UGT1A1基因型调整伊立替康剂量可优化疗效与安全性。
  • 主要终点为无进展生存期,次要终点包括总生存期等。

研究设计与样本

  • 前瞻性、多中心、随机2:1、对照、两平行臂临床试验。
  • 比较按UGT1A1基因型调整伊立替康剂量的FOLFIRI联合瑞戈非尼120mg与瑞戈非尼120mg单药。
  • 研究对象为经治的转移性结直肠癌患者。

关键数值与推荐

  • 主要终点为无进展生存期。
  • 次要终点包括总生存期、疾病控制率、至进展时间和治疗持续时间。
  • 瑞戈非尼剂量为120mg。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor receptor. A dose reduction from 160 mg to 120 mg regorafenib reduces regorafenib-associated adverse events (AEs). Dose adjustment of irinotecan in a 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) regimen on the basis of an individual uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) genotype provides optimal oncological outcomes with acceptable AEs. The aim of this study is to address the efficacy and safety of a dose-adjusted combination of regorafenib and FOLFIRI for patients with mCRC. METHODS: A prospective, multicenter, randomized in a 2:1 ratio, controlled, clinical trial with two parallel arms will be conducted to compare irinotecan dose-escalated FOLFIRI according to UGT1A1 genotyping plus 120 mg regorafenib with 120 mg regorafenib alone in previously treated patients with mCRC. The primary endpoint is progression-free survival, and the secondary endpoints are overall survival, disease control rate, time to progression, and duration of treatment. Safety assessments will also be recorded. DISCUSSION: Dose adjustment for regorafenib and irinotecan makes treatment-related AEs tolerable and makes the concomitant treatment practicable. This study will provide initial evidence regarding the efficacy and safety of a new combination of chemotherapy and a targeted agent for mCRC. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03880877. Prospectively registered on 19 March 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ma CJ, Chang TK, Tsai HL, et al. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. Trials. 2019. PMID: 31856912. doi:10.1186/s13063-019-3917-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。